Risto-Cel CAR-T Sickle Cell Disease — PatSnap Eureka
Risto-Cel CAR-T Therapy for Sickle Cell Disease: Phase I/II Pipeline Intelligence
Risto-cel (formerly nula-cel) is an autologous CAR-T–based gene editing approach targeting hematopoietic stem cell correction in sickle cell disease. Developed by Graphite Bio and acquired by Sana Biotechnology, it addresses the root HBB mutation driving vaso-occlusive crises and progressive organ damage.
SCD Gene Editing: Mechanistic Strategy Landscape
Relative pipeline activity across key therapeutic strategies for sickle cell disease correction
HBB Mutation, Hemoglobin S Polymerization, and the Vaso-Occlusive Crisis Cascade
Sickle cell disease is a monogenic hemoglobinopathy driven by a point mutation in the HBB gene, resulting in polymerization of deoxygenated hemoglobin S. This polymerization distorts red blood cell morphology, triggering recurrent vaso-occlusive crises (VOC) that cause progressive organ damage and early mortality. According to the World Health Organization, SCD is one of the most common severe monogenic disorders globally, affecting millions of people primarily in sub-Saharan Africa, the Middle East, and India.
Because the disease originates from a single defined genetic lesion in the HBB locus, it has long been considered an ideal candidate for gene correction strategies. The mechanistic goal of risto-cel and related approaches is to correct or compensate for this mutation at the level of hematopoietic stem cells (HSCs), which give rise to all red blood cells. Successful correction of HSCs would theoretically provide a durable, potentially curative outcome by eliminating the root cause of hemoglobin S production. The National Heart, Lung, and Blood Institute recognizes HSC-targeted gene therapy as a priority research area for SCD.
Key mechanistic targets across the SCD gene therapy field include BCL11A enhancer editing to derepress fetal hemoglobin, direct HBB gene correction via homology-directed repair, gamma-globin reactivation, and fetal hemoglobin (HbF) induction. Risto-cel's autologous CAR-T–based approach to HSC correction represents a distinct mechanistic strategy within this landscape, explored further through PatSnap's IP analytics platform.
From Nula-Cel to Risto-Cel: Graphite Bio, Sana Biotechnology, and the CEDAR Trial
Risto-cel is an autologous cell therapy strategy that evolved through a corporate acquisition, with the CEDAR Phase I/II trial serving as its primary clinical anchor.
Graphite Bio: Founding the Autologous HSC Gene Editing Program
Risto-cel was originally developed under the name nula-cel by Graphite Bio, a company focused on precision gene editing for hematopoietic stem cell diseases. The program centered on an autologous cell therapy strategy — collecting a patient's own HSCs, editing them ex vivo to correct the HBB mutation, and reinfusing the corrected cells. Graphite Bio filed patents and initiated the CEDAR Phase I/II clinical trial (NCT04819841) to evaluate safety and early efficacy signals in SCD patients.
Autologous · Ex Vivo · HBB CorrectionSana Biotechnology: Acquiring and Advancing the Risto-Cel Asset
Sana Biotechnology subsequently acquired the risto-cel program from Graphite Bio, incorporating it into a broader cell and gene therapy portfolio. The acquisition reflected Sana's strategic interest in hematopoietic stem cell correction approaches. Under Sana's stewardship, the asset was renamed risto-cel and continued clinical development within the CEDAR trial framework. Sana Biotechnology's pipeline development approach is tracked across PatSnap's assignee intelligence tools.
Sana Biotechnology · Pipeline AcquisitionCEDAR Trial: Phase I/II Safety and Durable Response Assessment
The CEDAR trial (NCT04819841) is a Phase I/II clinical study designed to evaluate risto-cel in sickle cell disease patients. As a Phase I/II study, its primary objectives encompass both safety characterization and early efficacy signals, including assessment of durable response — specifically, whether corrected HSCs engraft stably and reduce or eliminate vaso-occlusive crisis events. The trial represents the primary clinical data source for risto-cel's mechanistic proof-of-concept in human subjects. Clinical trial registries such as ClinicalTrials.gov provide the authoritative record.
Phase I/II · CEDAR · NCT04819841CAR-T–Based Gene Editing: A Novel Modality for HSC Correction
Risto-cel applies a CAR-T–based gene editing approach to hematopoietic stem cell correction — a mechanistically distinct strategy within the SCD gene therapy landscape. Unlike lentiviral gene addition (used in therapies such as betibeglogene) or CRISPR-based BCL11A disruption, risto-cel's approach involves targeted gene editing of patient-derived HSCs. This positions it alongside, but distinct from, other gene editing modalities tracked in the broader SCD IP landscape via PatSnap's life sciences intelligence platform.
CAR-T · Gene Editing · HSC CorrectionSCD Gene Therapy Search Dimensions and Mechanistic Coverage
Understanding the search architecture required to map the risto-cel landscape reveals the complexity of the SCD gene editing IP space and the breadth of mechanistic strategies in play.
Risto-Cel Pipeline: Three Core Search Dimensions
The risto-cel intelligence landscape spans three distinct search dimensions: core mechanisms, disease applications, and assignee IP activity.
SCD Gene Editing: Mechanistic Strategy Activity Levels
Relative pipeline activity across five mechanistic strategies for sickle cell disease correction, with risto-cel positioned in the autologous HSC CAR-T category.
How to Map the Risto-Cel and SCD Gene Editing IP Landscape
Five recommended search refinement strategies for retrieving comprehensive risto-cel, nula-cel, and SCD gene therapy patent intelligence from databases including EPO and USPTO.
Broaden Modality Framing Beyond Trade Names
Search for "sickle cell disease gene editing hematopoietic stem cell CAR-T" without proprietary drug names, as risto-cel and nula-cel may not be indexed under those trade names in patent databases. Mechanism-level terms retrieve broader and more complete prior art coverage.
Use INN and Mechanism Terms as Keyword Anchors
Try "BCL11A enhancer editing", "HBB gene correction", "gamma-globin reactivation", or "fetal hemoglobin induction" as keyword anchors. These mechanism-level terms are more consistently indexed across patent and literature databases than brand or program names.
Search Graphite Bio and Sana Biotechnology as Assignees Directly
Query "Graphite Bio" or "Sana Biotechnology" as assignee filters in patent databases (USPTO, EPO) separately from the semantic search layer. Assignee-level filtering at PatSnap's open API surfaces filings that may not appear in keyword searches.
Target Clinical Trial Registries for Literature Anchoring
ClinicalTrials.gov identifiers such as NCT04819841 (the CEDAR trial) may anchor literature that does not appear in patent or paper aggregators. Registry-linked publications often contain mechanistic detail absent from patent filings and can ground IP analysis in clinical context.
Risto-Cel vs. Key SCD Gene Therapy Modalities: Mechanistic Comparison
Positioning risto-cel's autologous CAR-T–based HSC correction approach relative to other mechanistic strategies active in the SCD gene therapy landscape.
| Therapeutic Strategy | Mechanistic Target | Cell Type Edited | Key Assignee(s) | Pipeline Stage | Search Approach |
|---|---|---|---|---|---|
| Risto-cel (nula-cel) | HBB gene correction via CAR-T–based editing | Autologous HSCs | Graphite Bio / Sana Biotechnology | Phase I/II (CEDAR, NCT04819841) | Assignee filter: Graphite Bio, Sana Biotechnology |
| BCL11A Enhancer Editing | BCL11A repressor disruption → HbF derepression | Autologous HSCs | Multiple (Broad Institute IP) | High pipeline activity | Keyword: "BCL11A enhancer editing" |
| Gamma-Globin Reactivation | HBG1/HBG2 promoter editing → γ-globin expression | Autologous HSCs | Multiple | Moderate pipeline activity | Keyword: "gamma-globin reactivation" |
| Fetal Hemoglobin Induction | Pharmacologic or genetic HbF upregulation | Erythroid progenitors | Multiple | Moderate pipeline activity | Keyword: "fetal hemoglobin induction" |
| Lentiviral Gene Addition | Functional HBB gene insertion via lentiviral vector | Autologous HSCs | bluebird bio (betibeglogene) | Approved (Zynteglo) | Keyword: "lentiviral HBB SCD" |
| CRISPR/Cas9 BCL11A Editing | BCL11A erythroid enhancer disruption via CRISPR | Autologous HSCs | Vertex / CRISPR Therapeutics | Approved (Casgevy) | Keyword: "CRISPR BCL11A SCD" |
Map the Full SCD Gene Therapy IP Landscape with PatSnap Eureka
From risto-cel assignee filings to CRISPR-based BCL11A editing patents — all in one platform.
Risto-Cel CAR-T Sickle Cell Disease — key questions answered
Risto-cel, formerly known as nula-cel, is a CAR-T–based gene editing approach advanced by Graphite Bio and subsequently acquired by Sana Biotechnology. It represents a novel autologous cell therapy strategy targeting hematopoietic stem cell correction in sickle cell disease.
Sickle cell disease is a monogenic hemoglobinopathy driven by a point mutation in the HBB gene, resulting in polymerization of deoxygenated hemoglobin S and recurrent vaso-occlusive crises that cause progressive organ damage and early mortality.
The risto-cel clinical program is associated with the CEDAR trial, referenced under ClinicalTrials.gov identifier NCT04819841, which evaluates this autologous cell therapy approach in sickle cell disease patients.
Risto-cel was originally advanced by Graphite Bio and was subsequently acquired by Sana Biotechnology, which continues development of this autologous CAR-T–based gene editing approach for sickle cell disease.
Key mechanistic approaches in SCD gene therapy include BCL11A enhancer editing, HBB gene correction, gamma-globin reactivation, and fetal hemoglobin induction, as well as broader hematopoietic stem cell correction strategies.
Vaso-occlusive crises (VOC) are recurrent painful episodes caused by polymerization of deoxygenated hemoglobin S in sickle cell disease. These crises cause progressive organ damage and early mortality, and reducing or eliminating VOC episodes is a primary endpoint in SCD gene therapy trials.
Still have questions about risto-cel or the SCD gene therapy landscape? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About Risto-CelAccelerate Your SCD Gene Therapy Pipeline Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map CAR-T, gene editing, and hematopoietic stem cell therapy IP landscapes — including risto-cel and the full SCD competitive field.
References
- ClinicalTrials.gov — CEDAR Trial NCT04819841: Risto-cel (nula-cel) Phase I/II Study in Sickle Cell Disease
- World Health Organization — Sickle Cell Disease Fact Sheet
- National Heart, Lung, and Blood Institute (NHLBI) — Sickle Cell Disease Overview and Gene Therapy Research
- European Patent Office (EPO) — Patent Database for SCD Gene Editing and Hematopoietic Stem Cell Therapy
- PatSnap Life Sciences Intelligence Platform — SCD and Gene Therapy Pipeline Analytics
All data and analytical frameworks on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Clinical trial information should be verified directly with ClinicalTrials.gov for the most current status.
PatSnap Eureka searches patents and research to answer instantly.